Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CRNX
Crinetics Pharmaceuticals, Inc.
stock NASDAQ

At Close
Jul 6, 2026 3:59:58 PM EDT
42.01USD-0.509%(-0.22)4,856,294
42.01Bid   48.60Ask   6.59Spread
Pre-market
Jul 6, 2026 9:25:30 AM EDT
42.30USD+0.166%(+0.07)498
After-hours
Jul 6, 2026 4:59:48 PM EDT
83.93USD+99.762%(+41.92)1,769,198
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 12, 2022
07:30AM EST  - Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022   GlobeNewswire Inc
Jan 5, 2022
07:30AM EST  Crinetics Pharmaceuticals Adds Board Member with Global Rare   GlobeNewswire Inc
Nov 30, 2021
04:51PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021   Benzinga
04:44PM EST  JMP Securities Initiates Coverage On Crinetics Pharmaceuticals with Market Outperform Rating, Announces Price Target of $43   Benzinga
Nov 23, 2021
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021   Benzinga
07:24AM EST  Evercore ISI Group Initiates Coverage On Crinetics Pharmaceuticals with Outperform Rating, Announces Price Target of $68   Benzinga
Nov 18, 2021
08:00AM EST  Crinetics Pharmaceuticals to Present at the 4th Annual Evercore   GlobeNewswire Inc
Nov 8, 2021
08:07AM EST  Crinetics Pharmaceuticals Presenting New Data From Open Label Extension Trial Of Paltusotine In Acromegaly At Society For Endocrinology BES Congress   Benzinga
08:00AM EST  Crinetics Pharmaceuticals Presenting New Data from Open Label   GlobeNewswire Inc
07:24AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:04AM EST  HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $35   Benzinga
Nov 5, 2021
09:42AM EDT  Crinetics Pharmaceuticals Q3 EPS $(0.73) Down From $(0.56) YoY   Benzinga
08:00AM EDT  Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts   GlobeNewswire Inc
Oct 30, 2021
01:30PM EDT  Last Week's Notable Insider Buys: Beacon Roofing Supply, Enfusion, Nerdy And More   Benzinga
Oct 25, 2021
04:01PM EDT  Crinetics Pharmaceuticals Announces Closing of Public Offering of   GlobeNewswire Inc
Oct 21, 2021
12:12PM EDT  Crinetics Pharmaceuticals Prices 7.576M Share Common Stock Offering At $19.80/Share   Benzinga
12:11PM EDT  The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO   Benzinga
12:10PM EDT  Crinetics Pharma Reports Offering Of Common Stock, No Size Disclosed   Benzinga
08:22AM EDT  Crinetics Pharmaceuticals Announces Pricing of Public Offering of   GlobeNewswire Inc
Oct 20, 2021
04:02PM EDT  Crinetics Pharmaceuticals Announces ProposedPublic   GlobeNewswire Inc
Oct 19, 2021
08:20AM EDT  Crinetics Spins Off Radiopharmaceuticals Efforts Into New Company   Benzinga
Oct 18, 2021
04:01PM EDT  Radionetics Oncology Emerges From Crinetics Pharmaceuticals With A Platform And Deep Pipeline Of Nonpeptide Targeted Radiopharmaceutical Drug Candidates For Precision Oncology   Benzinga
04:00PM EDT  Co-founded by Crinetics, 5AM Ventures and Frazier Healthcare Partners, the New Company Launches with $30M in Initial Financing Provided by 5AM and Frazier   GlobeNewswire Inc
Sep 27, 2021
07:34AM EDT  Crinetics Pharmaceuticals To Unveil Parathyroid Hormone Receptor Antagonist Program At American Society For Bone And Mineral Research Annual Meeting Oct. 1-4   Benzinga
07:30AM EDT  Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone   GlobeNewswire Inc
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 15, 2021
04:02PM EDT  Crinetics Pharmaceuticals' Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept With Strong Dose-dependent Suppression Of Insulin Secretion In Phase 1 Single Ascending Dose Study   Benzinga
04:01PM EDT  CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms   GlobeNewswire Inc
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 7, 2021
07:30AM EDT  Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the following investor conferences in the month of September:   GlobeNewswire Inc
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
07:36AM EDT  Crinetics Pharmaceuticals Appoints Jeff Knight As Chief Operating Officer   Benzinga
07:30AM EDT  Crinetics Pharmaceuticals Expands Executive Team with Addition of   GlobeNewswire Inc
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
07:19AM EDT  Crinetics' Single Ascending Dose Data Shows Proof Of ACTH Antagonism In Healthy Volunteers   Benzinga
Aug 10, 2021
04:25PM EDT  Crinetics Pharmaceuticals Q2 EPS $(0.70) Down From $(0.53) YoY   Benzinga
04:09PM EDT  Crinetics Pharmaceuticals' Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study   Benzinga
04:02PM EDT  Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial   GlobeNewswire Inc
04:01PM EDT  Crinetics Pharmaceuticals Oral ACTH Antagonist,   GlobeNewswire Inc
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
07:52AM EDT  Crinetics Reports $15M Private Placement With Frazier Healthcare Partners   Benzinga
07:30AM EDT  Crinetics Pharmaceuticals Announces $15.0 Million Private   GlobeNewswire Inc
Jul 8, 2021
10:27AM EDT  UPDATE: SVB Leerink On Crinetics Pharma: Firm Believes Phase 1 Single Ascending Dose and Multiple Ascending Dose Healthy Volunteer Data For Cushing's Disease 'Could Meaningfully De-Risk The Pipeline'   Benzinga
Jun 28, 2021
07:35AM EDT  Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly   Benzinga
07:30AM EDT  - If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option -   GlobeNewswire Inc
Jun 18, 2021
12:47PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021   Benzinga
06:56AM EDT  JP Morgan Upgrades Crinetics Pharmaceuticals to Overweight, Announces $28 Price Target   Benzinga
Jun 16, 2021
08:41AM EDT  Crinetics Appoints Garlan Adams As General Counsel   RTTNews
08:30AM EDT  Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel   GlobeNewswire Inc
May 6, 2021
04:56PM EDT  Crinetics Pharmaceuticals Q1 EPS $(0.69) Up From $(0.71) YoY   Benzinga
May 3, 2021
02:59PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2021   Benzinga
07:15AM EDT  JonesTrading Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $42   Benzinga
Apr 12, 2021
04:05PM EDT  Crinetics Pharmaceuticals Announces Closing of Common Stock Offering   GlobeNewswire Inc
Apr 10, 2021
02:03PM EDT  The Past Week's Notable Insider Buys Included Biotechs, Public Offerings, A SPAC And More   Benzinga
Apr 9, 2021
11:18AM EDT  Insider Buys Crinetics Pharmaceuticals Shares   Benzinga
Apr 8, 2021
09:21AM EDT  Crinetics Pharmaceuticals Wednesday Announced Pricing Of Public Offering Of ~4.56M Shares Of Common Stock At $16.44/Share   Benzinga
08:14AM EDT  The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data   Benzinga
Apr 7, 2021
06:31PM EDT  Crinetics Pharmaceuticals Announces Pricing of Public Offering of   GlobeNewswire Inc
Mar 30, 2021
04:15PM EDT  Crinetics Pharmaceuticals Q4 EPS $(0.66) Misses $(0.58) Estimate   Benzinga
04:05PM EDT  Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting   GlobeNewswire Inc
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
04:04AM EDT  Earnings Scheduled For March 30, 2021   Benzinga
Mar 27, 2021
01:01PM EDT  The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week   Benzinga
Mar 24, 2021
07:10AM EDT  Crinetics Pharmaceuticals to Host Webcast and Conference Call to   GlobeNewswire Inc
Mar 22, 2021
07:18AM EDT  Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021   Benzinga
Mar 12, 2021
07:11AM EST  Crinetics Pharma Highlights Upcoming Oral, Poster Presentations At Endocrine Society's Annual ENDO Congress Mar. 20   Benzinga
07:10AM EST  Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO   GlobeNewswire Inc
Feb 4, 2021
07:27AM EST  Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing's Disease Advances into Phase 1 Study   Benzinga
07:10AM EST  Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital   GlobeNewswire Inc
Feb 3, 2021
07:15AM EST  Crinetics Pharmaceuticals Advances CRN04777 For Congenital Hyperinsulinism Into Phase 1 Study   Benzinga
07:10AM EST  Crinetics Pharmaceuticals Advances CRN04777   GlobeNewswire Inc
Jan 6, 2021
07:05AM EST  - Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 -   GlobeNewswire Inc
Nov 23, 2020
07:30AM EST  Crinetics Pharmaceuticals(Nasdaq:CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:   GlobeNewswire Inc
Nov 16, 2020
07:46AM EST  Crinetics Appoints Peter Trainer VP Of Clinical Endocrinology   RTTNews
07:30AM EST  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Peter Trainer, MD, FRCPE to the position of Vice President of Clinical Endocrinology.   GlobeNewswire Inc
Nov 13, 2020
07:30AM EST  Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral   GlobeNewswire Inc
Nov 6, 2020
08:41AM EST  Crinetics Q3 Net Loss $18.3 Mln Vs Loss $14.4 Mln Last Year   RTTNews
08:32AM EST  Crinetics Pharmaceuticals Q3 EPS $(0.56) Up From $(0.60) YoY   Benzinga
08:31AM EST  Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly   GlobeNewswire Inc
Oct 26, 2020
09:54AM EDT  Crinetics Pharmaceuticals shares are trading higher after the company announced its phase 2 ACROBAT study met its primary endpoint.   Benzinga
07:11AM EDT  Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint   Benzinga
07:02AM EDT  ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy   GlobeNewswire Inc
Sep 21, 2020
07:31AM EDT  Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation From FDA For CRN04777 For The Treatment Of Congenital Hyperinsulinism   Benzinga
07:30AM EDT  Crinetics Pharmaceuticals Receives Rare Pediatric Disease   GlobeNewswire Inc
Sep 4, 2020
07:48AM EDT  Crinetics Provides New Data From Paltusotine And ACTH Antagonist Development Programs   RTTNews
07:32AM EDT  Crinetics Pharmaceuticals To Present New Data From Paltusotine And ACTH Antagonist Development Programs At European Congress Of Endocrinology Sept. 5-9   Benzinga
07:30AM EDT  Crinetics Pharmaceuticals Provides New Data from Paltusotine and   GlobeNewswire Inc
Sep 3, 2020
05:57PM EDT  Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:   GlobeNewswire Inc
07:40AM EDT  Crinetics Pharma Appoints Camille Bedrosian To Board Of Directors   RTTNews
07:30AM EDT  Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille   GlobeNewswire Inc
Aug 7, 2020
07:41AM EDT  Crinetics Pharmaceuticals Q2 EPS $(0.53) Down From $(0.51) YoY   Benzinga
07:30AM EDT  Paltusotine received Orphan Drug Designation for the treatment of acromegaly   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC